UCB and Proteros expand successful protein x-ray crystallography collaboration

Collaboration aims to accelerate drug discovery for new therapies in central nervous system (CNS) disorders and immunology diseases

20-Sep-2012 - Germany

UCB and Proteros biostructures GmbH announced expansion of their ongoing structural biology collaboration to include additional therapeutic areas. Since 2007, Proteros has supported discovery programmes for UCB in the area of immunology, by solving complex unpublished protein structures to give UCB scientists insight on how to optimise promising novel compounds. The collaboration has now expanded to include extra programmes/ targets and additionally includes CNS discovery research.

As the drive for increased productivity within the pharmaceutical industry continues, technologies that can improve the success rates in the lead discovery and optimisation process remain a key focus. Over several years, protein crystallography has shown itself as one of these technologies. It is important as it allows scientists to directly visualize the three-dimensional structures and interactions of proteins, including enzymes, receptors and hormones. Being able to ‘see’ pharmacological interactions at the molecular level provides knowledge that enables structure-based drug design. Taking advantage of structural information and applying it in structure-based approaches to making new medicines promises to reduce the time and cost required to produce a medicine and deliver medicines that are more selective, potentially with fewer undesirable side effects.

The research alliance between Proteros and UCB adds to UCB’s open innovation model that aims to generate new knowledge and capitalize on external scientific advances, resources and expertise through dedicated collaborations that complement the company’s unique internal capabilities and expertise.

Other news from the department business & finance

More news from our other portals